Published in J Clin Invest on November 01, 2007
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Shared circuitry: developmental signaling cascades regulate both embryonic and adult coronary vasculature. Circ Res (2009) 1.20
Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest (2007) 1.18
Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des (2011) 1.16
Angiogenesis in the infarcted myocardium. Antioxid Redox Signal (2012) 1.15
Endothelial-specific expression of WNK1 kinase is essential for angiogenesis and heart development in mice. Am J Pathol (2009) 1.12
Cell communications in the heart. Circulation (2010) 1.09
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med (2014) 1.08
Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res (2012) 1.07
NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest (2013) 0.99
VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr (2009) 0.98
Three-dimensional culture alters primary cardiac cell phenotype. Tissue Eng Part A (2010) 0.92
Molecular basis for proline- and arginine-rich peptide inhibition of proteasome. J Mol Biol (2008) 0.92
Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther (2012) 0.88
Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther (2011) 0.87
Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med (2008) 0.86
AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy. Mol Ther (2012) 0.86
Endothelium as master regulator of organ development and growth. Vascul Pharmacol (2008) 0.86
Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc (2015) 0.85
Impaired Ca(2+)-handling in HIF-1alpha(+/-) mice as a consequence of pressure overload. Pflugers Arch (2009) 0.84
Activation of hypoxia-inducible factor-2 in adipocytes results in pathological cardiac hypertrophy. J Am Heart Assoc (2013) 0.84
Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase. J Cell Biochem (2012) 0.83
Genetic deletion of aquaporin-1 results in microcardia and low blood pressure in mouse with intact nitric oxide-dependent relaxation, but enhanced prostanoids-dependent relaxation. Pflugers Arch (2013) 0.83
miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Sci Rep (2016) 0.83
VEGF-B: a thing of beauty. Cell Res (2010) 0.82
Permanent ligation of the left anterior descending coronary artery in mice: a model of post-myocardial infarction remodelling and heart failure. J Vis Exp (2014) 0.80
BMPER regulates cardiomyocyte size and vessel density in vivo. Cardiovasc Pathol (2012) 0.80
Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications. Trends Pharmacol Sci (2015) 0.80
Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart. J Am Heart Assoc (2013) 0.79
"On-target" cardiac effects of anticancer drugs: lessons from new biology. J Am Coll Cardiol (2012) 0.79
Suicide gene-mediated sequencing ablation revealed the potential therapeutic mechanism of induced pluripotent stem cell-derived cardiovascular cell patch post-myocardial infarction. Antioxid Redox Signal (2014) 0.78
Angiogenic biomarkers in children with congenital heart disease: possible implications. Ital J Pediatr (2010) 0.77
Cardiac Morphology and Function, and Blood Gas Transport in Aquaporin-1 Knockout Mice. Front Physiol (2016) 0.77
Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. PLoS One (2015) 0.76
Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy. PPAR Res (2016) 0.75
G protein, phosphorylated-GATA4 and VEGF expression in the hearts of transgenic mice overexpressing β1- and β2-adrenergic receptors. Mol Med Rep (2017) 0.75
Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines. Heart Vessels (2014) 0.75
Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science (2001) 8.53
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest (2005) 5.48
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature (2007) 4.63
Signaling pathways for cardiac hypertrophy and failure. N Engl J Med (1999) 3.97
Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation (2000) 3.68
Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension (2006) 3.01
Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev (2006) 2.96
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature (2005) 2.55
Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ Res (2005) 2.34
Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem (2002) 2.21
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Conditional transgene expression in the heart. Circ Res (1996) 1.79
Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation (2001) 1.77
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology (1998) 1.28
Differential expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) in murine tissues. Microcirculation (1998) 1.25
Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res (2003) 1.17
Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun (2003) 1.05
PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol (2001) 1.00
Microvascular involvement in cardiac pathology. J Mol Cell Cardiol (1998) 0.98
Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec (1998) 0.91
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Tissue-engineered lungs for in vivo implantation. Science (2010) 5.90
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science (2009) 5.07
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature (2010) 3.40
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev (2004) 3.29
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature (2012) 2.83
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
Syndecans: new kids on the signaling block. Circ Res (2005) 2.43
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell (2011) 2.42
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res (2004) 2.29
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell (2012) 2.14
Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation (2005) 2.13
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
Medical device development: from prototype to regulatory approval. Circulation (2004) 1.90
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88